Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate.

TC, Stock; BJ, Bloom; N, Wei; S, Ishaq; W, Park; X, Wang; P, Gupta; CA, Mebus

doi:10.3899/jrheum.110874

Public

Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate.

Published in The Journal of rheumatology • Mar 1, 2012

Authors:

Stock TC

Bloom BJ

Wei N

Abstract

<h4>Objective</h4>To evaluate efficacy and safety of CE-224,535, a selective P2X(7) receptor antagonist, versus placebo, in patients with active rheumatoid arthritis (RA) and inadequate response to methotrexate (MTX).<h4>Methods</h4>In our phase IIA study (ClinicalTrials.gov no. NCT00628095; A634100...

View

Open Access

Generate AI Take for this paper

Highlights, strengths & weaknesses, commercial applications, and societal impact — written for this paper on demand.

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!